Decibel therapeutics investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of decibel therapeutics, inc. - dbtx

New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of decibel therapeutics, inc. (nasdaqgs: dbtx) to regeneron pharmaceuticals, inc. (nasdaqgs: regn). under the terms of the proposed transaction, shareholders of decibel will receive only $4.00 in cash for each share of decibel that they own, with an additional non-tradeable contingent value right (cvr) to receive.
REGN Ratings Summary
REGN Quant Ranking